Dr Mark Treherne & Dr David Brown to lead discussion at Life Sciences Dinner - 14/05/17

❰ Back

We are pleased to announce that Dr Mark Treherne and Dr David Brown will be leading discussion at our forthcoming Life Sciences Dinner, on the topic of Structuring your board for transition.

Mark Treherne has over 25 years’ experience in the discovery of novel treatments for diseases of the nervous system.  Following an early career at Pfizer, he founded Cambridge Drug Discovery in 1997 and served as CEO, leading the growth of the company to exit to BioFocus in 2001 for £28 million. Over the past 15 years, Mark has helped to raise over £150 million for various early-stage biotechnology companies and has served on the boards of 16 private and public companies.

David Brown has served with 4 of the top 10 pharmaceutical companies during a career which has so far spanned more than 40 years. At Pfizer he was named co-inventor on the patent for Viagra. He played a pivotal role in the discovery of Relpax, a treatment for migraine. Together these drugs have achieved sales of over $30 billion. At Roche, David was a Director of the company and Global Head of Drug Discovery.  More recently, he has co-founded companies including Crescendo Biologics and Healx.  David is an active angel investor, and has coached CEOs and entrepreneurs at the Judge Business School.  David currently serves as Chair of Healx, ProFactor Pharma and Babraham Institute Enterprise Ltd.

Discussion over dinner will be moderated by Nooman Haque, Director of Life Sciences for Silicon Valley Bank in the UK.  The Life Sciences Dinner is organised and hosted by Bailey Fisher Executive Search in association with Silicon Valley Bank and Taylor Wessing.

Share Button
❰ Back